Noventra Pharma Retrexa (44mg Prefilled Pen – Retatrutide + Naltrexone)

Retrexa is a combination formulation supplied in a pre-reconstituted pen format for controlled dispensing. It combines retatrutide, a multi-receptor peptide investigated for activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, with naltrexone, a centrally acting compound studied for its interaction with neuroregulatory pathways.

This combination is investigated for its role in metabolic signalling and central nervous system pathways related to energy balance and regulatory processes.

Key Features:

• 44mg combined formulation: retatrutide + naltrexone

• Multi-receptor activity: GLP-1, GIP, and glucagon receptor pathways

• Includes centrally acting component (naltrexone)

• Prefilled pen format for controlled and consistent application

• Investigated for roles in metabolic and neuroregulatory signalling pathways

• Studied in relation to energy balance and endocrine processes

Suggested Use:
For use under the guidance of a qualified professional. Protocols vary depending on application and individual requirements.

Storage:

• Store at 2–8°C at all times (refrigerated)

• Do not freeze

• Protect from light

• Avoid repeated temperature fluctuations

• Use within a limited timeframe once in use (based on formulation stability)

Important Information:
This product contains an investigational peptide component and a centrally acting compound and should be used within appropriate professional and regulatory frameworks. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.